Levetiracetam

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Dyskinesia, Medication-induced

Conditions

Dyskinesia, Medication-induced

Trial Timeline

May 1, 2005 → Dec 1, 2005

NCT ID

NCT00175955

About Levetiracetam

Levetiracetam is a phase 2 stage product being developed by UCB for Dyskinesia, Medication-induced. The current trial status is completed. This product is registered under clinical trial identifier NCT00175955. Target conditions include Dyskinesia, Medication-induced.

What happened to similar drugs?

3 of 9 similar drugs in Dyskinesia, Medication-induced were approved

Approved (3) Terminated (1) Active (6)

🔄Levodopa-carbidopa intestinal gelAbbViePhase 3

🔄levetiracetam + placeboUCBPhase 3

✅Valbenazine Oral CapsuleNeurocrine BiosciencesApproved

🔄NBI-98854Neurocrine BiosciencesPhase 3

✅Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved

🔄NBI-98854 + PlaceboNeurocrine BiosciencesPhase 3

🔄Placebo + ValbenazineNeurocrine BiosciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03340064	Phase 3	Completed	Nov 30, 2017	Jul 28, 2023	Partial Seizures
NCT01618877	Phase 1	Completed	May 1, 2012	Jul 1, 2012	Human Volunteers
NCT01407523	Phase 2	Completed	Jul 1, 2011	Feb 1, 2012	Epilepsy
NCT01398956	Phase 3	Completed	Jun 1, 2011	Apr 1, 2016	Epilepsy
NCT01292837	Phase 3	Completed	Feb 1, 2011	Jun 1, 2013	Epilepsy
NCT01063764	Phase 3	Completed	Jan 1, 2010	Oct 1, 2013	Epilepsy
NCT00505934	Phase 2	Completed	May 1, 2008	Mar 1, 2010	Epilepsy
NCT00627133	Phase 2	Withdrawn	Feb 1, 2008	—	Seizure, Alcohol Related
NCT00535392	Phase 2	Completed	Sep 1, 2007	Feb 1, 2010	Epilepsy
NCT00376766	Phase 3	Terminated	Feb 1, 2007	Apr 1, 2008	Epilepsy
NCT00361010	Pre-clinical	Completed	Dec 1, 2006	Dec 1, 2007	Epilepsy
NCT01318408	Approved	Completed	Nov 1, 2006	Mar 1, 2008	Epilepsy
NCT00367432	Phase 3	Completed	Jul 1, 2006	Dec 1, 2010	Epilepsies
NCT00291655	Phase 3	Completed	Jun 1, 2006	Apr 1, 2008	Epilepsy
NCT00324454	Phase 2	Completed	May 1, 2006	Jun 1, 2008	Motor Neuron Disease
NCT00319605	Pre-clinical	Completed	Apr 1, 2006	Jul 1, 2006	Epilepsy
NCT00307450	Approved	Completed	Mar 1, 2006	Jul 1, 2009	Parkinson's Disease
NCT00279617	Phase 3	Completed	Jan 1, 2006	Mar 1, 2009	Panic Disorder
NCT00325182	Approved	Completed	Jan 1, 2006	Oct 1, 2009	Alcoholism
NCT00252954	Approved	Completed	Nov 1, 2005	Dec 1, 2008	Injuries, Spinal Cord

Competing Products

20 competing products in Dyskinesia, Medication-induced

See all competitors

Product	Company	Stage	Hype Score
DSP-9632P 27.5 mg + DSP-9632P 82.5 mg + Placebo + DSP-9632P 55.0 mg + Levodopa formulation	Sumitomo Pharma	Phase 1	29
Levodopa-carbidopa intestinal gel	AbbVie	Phase 3	40
Sarizotan	Merck	Pre-clinical	18
AFQ056	Novartis	Phase 2	35
AFQ056 + Placebo	Novartis	Phase 2	35
AQW051 + AQW051 + Placebo	Novartis	Phase 2	35
AFQ056 + Placebo	Novartis	Phase 2	35
VX-371 + Hypertonic Saline + Placebo (0.17% saline) + VX-371 + HS + Ivacaftor	Vertex Pharmaceuticals	Phase 2	35
levetiracetam + placebo	UCB	Phase 3	40
Levetiracetam + Placebo	UCB	Phase 2	31
Valbenazine	Neurocrine Biosciences	Phase 1	18
Valbenazine Oral Capsule	Neurocrine Biosciences	Approved	32
NBI-98854 + NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
NBI-98854 + NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
NBI-98854	Neurocrine Biosciences	Phase 3	37
Valbenazine + Placebo oral capsule	Neurocrine Biosciences	Approved	40
NBI-98854	Neurocrine Biosciences	Phase 2	32
NBI-98854 + Placebo	Neurocrine Biosciences	Phase 3	37
Placebo + Valbenazine	Neurocrine Biosciences	Phase 3	41
Valbenazine	Neurocrine Biosciences	Phase 3	37